Oncology Clinical Pathways

Malignant Melanoma

November 2024 – V2.2024

Table of Contents

Presumptive Conditions 3

Initial Evaluation 4

Adjuvant Treatment and Follow-Up 5

Stage III 6

Stage III SNL Positive Approach 7

Stage III Clinically Positive Approach 8

Recurrent Disease 9

Metastatic First Line 10

Metastatic Second Line, Progression After Ipilimumab and Nivolumab 11

Metastatic Second Line, Progression After Dabrafenib and Trametinib 12

Metastatic Second Line, Progression After PD-1 Alone 13

Metastatic Second Line, Progression After Nivolumab and Relatimab 14

Intracranial 15

Mucosal 16

Ocular 17

Uveal Metastatic or Recurrent 18

Molecular Testing 19

Molecular Testing Table 20

Malignant Melanoma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Gulf War and Post 9/11 Veterans

If the patient served on or after Sept. 11, 2001, in Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Uzbekistan, or Yemen or if you served in the *Southwest Asia theater of operations, or Somalia, on or after Aug. 2, 1990, specific conditions include:

- Melanoma

* The Southwest Asia theater of operations refers to Iraq, Kuwait, Saudi Arabia, the neutral zone between Iraq and Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above these locations.

For more information, please visit U.S. Department of Veterans Affairs - Presumptive Disability Benefits (va.gov)

Malignant Melanoma – Initial Evaluation



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Initial Evaluation** diagnosis of cutaneous melanoma should be obtained by a method to adequately assess depth

[b] **Microsatellitosis or Satellitosis** is N1c disease

[c] **≥2mm** systemic imaging can be considered for very high risk features prior to excision

[d] **Alternatives** include Mohs depending on location; if patient is not a surgical candidate consider imiquimod therapy for in situ disease

[e] **Sentinel Lymph Node Biopsy** age and fragility of the patient may be considered when deciding to pursue sentinel lymph node biopsy

Malignant Melanoma – Adjuvant Treatment and Follow-Up



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Recurrent Disease Pathway** use of neoadjuvant immunotherapy may be considered based on clinical scenario

[b] **Stage II Adjuvant Treatment** with pembrolizumab in Stage II melanoma has not yet been associated with improvements in overall survival and have been approved based on improvements in recurrence free survival alone; discussions of this should be highlighted with patients, and observation is a reasonable approach

[c] **Stage III Adjuvant Treatment** with pembrolizumab in Stage III melanoma has been associated with improvements in relapse free survival compared to placebo and compared to ipilimumab (known to improve overall survival in adjuvant treatment); for patients with small burden Stage IIIA disease (nonulcerated primary and <1mm in a LN), observation is reasonable; all Stage III patients warrant careful consideration of risks versus benefits of treatment toxicity

[d] **Candidate for Immunotherapy** patient without active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation or solid organ transplant

[e] **Second Regimen** of systemic adjuvant treatment following a recurrence preceded by initial systemic adjuvant therapy is to be considered on a case by case basis

[f] **Cross-Sectional Imaging** includes PET/CT or CT imaging of the chest, abdomen, and pelvis; neck or brain imaging may be considered as necessary

[g] **Consider** alternate BRAF/MEK inhibitors if significant intolerance is encountered despite dose reductions with dabrafenib and trametinib

Malignant Melanoma – Stage III



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

Malignant Melanoma – Stage III SLN Positive Approach



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Systemic Imaging** to include whole body PET/CT, or CT imaging and brain MRI;

[b] **Lymph Node Surveillance** to include ultrasound every 4 months for the first 2 years (involved LN basin ultrasound if possible at local center), cross-sectional imaging may replace ultrasound surveillance; observe to 5 years with imaging as directed by symptoms or at least every 6 months for 3 years, then at least yearly to 5 years, observation should be a component of any treatment strategy; LN dissection may be considered in high risk clinical scenarios

[c] **Stage III Adjuvant Treatmen**t with pembrolizumab in Stage III melanoma has been associated with improvements in relapse free survival compared to placebo and compared to ipilimumab (known to improve overall survival in adjuvant treatment); for patients with small burden Stage IIIA disease (non-ulcerated primary and <1mm in a LN), observation is reasonable; all Stage III patients warrant careful consideration of risks versus benefits of treatment toxicity

[d] **Observation Alone** if Stage IIIA if small volume sentinel lymph node disease (< 1mm) observation is reasonable and often preferred

[e] **Observation if Stage IIIA** includes: PET/CT or CT imaging (every 6-12 months for up to five years); **Stage IIIB** includes: PET/CT or CT imaging and CNS imaging as necessary (every 6-12 months for up to five years); **Stage IIIC/IIID**: PET/CT or CT imaging and CNS imaging as necessary (every 3-12 months for up to five years)

[f] **Candidate for Immunotherapy** patient without active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation or solid organ transplant

[g] **Dabrafenib and Trametinib** alternate BRAF inhibitors may be considered for patient intolerance or preference (encorafenib and binimetinib or vemurafenib and cobimetinib)

Malignant Melanoma – Stage III Clinically Positive Approach



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Clinically Positive** defined as palpable lymph node or found on imaging and pathologically confirmed

[b] **Systemic Imaging** to include whole body PET/CT and brain MRI

[c] **Candidate for Immunotherapy** patient without active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic HSCT/solid organ transplant

[d] **Neoadjuvant pembrolizumab** use of neoadjuvant immunotherapy should consider the clinical situation and progression to immediate resection is appropriate in some patients; the most appropriate treatment regimen and length of therapy prior to resection remains undefined, alternate choices may be appropriate in select circumstances

[e] **Candidate for Dual Agent Immunotherapy** patients with ECOG performance status 0-1, lack of active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic HSCT/solid organ transplant

[f] **Observation Alone** if Stage IIIA if small volume SLN disease (< 1mm) observation is reasonable and often preferred

[g] **Adjuvant Therapy** choice should consider prior lines and timing of potential adjuvant treatment include pembrolizumab, nivolumab, dabrafenib/trametinib if BRAF V600E/K + observation; discussion of locoregional therapy IPILIMUMAB if prior PD-1

[h] **Observation** if **Stage IIIA** includes: PET/CT or CT imaging (every 6-12 months for up to five years); **Stage IIIB** includes: PET/CT or CT imaging and CNS imaging as necessary (every 6-12 months for up to five years); **Stage IIIC/IID**: PET/CT or CT imaging and CNS imaging as necessary (every 3-12 months for up to five years)

[i] **Dabrafenib and Trametinib** alternate BRAF inhibitors may be considered for patient intolerance or preference (Encorafenib/Binimetinib, Vemurafenib/Cobimetinib)

[j] **Targeted Therapy after Neoadjuvant Immunotherapy** the use of adjuvant targeted therapy following neoadjuvant immunotherapy is not standard but can be considered in appropriate situations for those no longer eligible for completion of adjuvant immunotherapy or poor responders

Malignant Melanoma – Recurrent Disease



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Systemic Imaging** to include PET/CT, or CT imaging and brain MRI ongoing observation (5 years); primary site recurrences may not require full systemic imaging

[b] **Recurrent Disease** use of neoadjuvant therapy may be considered based on clinical scenario

[c] **Re-Excise to Appropriate Margins** consider sentinel lymph node biopsy

[d] **Adjuvant Therapy** choice should consider prior lines and timing of potential adjuvant treatment include pembrolizumab, nivolumab, dabrafenib/trametinib if BRAF V600E/K + observation; discussion of locoregional therapy ipilimumab if prior PD-1

Malignant Melanoma – Metastatic First Line



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Candidate for Immunotherapy** patient without active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic HSCT/solid organ transplant

[b] **Neoadjuvant pembrolizumab** use of neoadjuvant immunotherapy should consider the clinical situation and progression to immediate resection is appropriate in some patients; the most appropriate treatment regimen and length of therapy prior to resection remains undefined, alternate choices may be appropriate in select circumstances

[c] **Observation** if **Stage IIIA** includes: PET/CT or CT imaging (every 6-12 months for up to five years); **Stage IIIB** includes: PET/CT or CT imaging and CNS imaging as necessary (every 6-12 months for up to five years); **Stage IIIC/IID/IV**: PET/CT or CT imaging and CNS imaging as necessary (every 3-12 months for up to five years)

[d] **Candidate for Dual Agent Immunotherapy** patients with ECOG performance status 0-1, lack of active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic HSCT/solid organ transplant

[e] **Extensive Disease Burden** presence of brain metastases or clinically symptomatic sites of disease

[f] **Dabrafenib and Trametinib** alternate BRAF inhibitors may be considered for patient intolerance or preference (Encorafenib/Binimetinib, Vemurafenib/Cobimetinib)

[g] **Targeted Therapy after Neoadjuvant Immunotherapy** the use of adjuvant targeted therapy following neoadjuvant immunotherapy is not standard but can be considered in appropriate situations for those no longer eligible for completion of adjuvant immunotherapy or poor responders

Malignant Melanoma – Metastatic Second Line Progression After Ipilimumab and Nivolumab



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Progression** time, rate, and site of progression should be considered when deciding on change in systemic treatment or locoregional treatment

[b] **BRAF Status** decision between second line targeted therapy and escalation to dual agent immunotherapy (nivolumab and relatlimab or ipilimumab and nivolumab) should take into account disease burden, rate of progression, and tolerance of prior lines of therapy

[c] **Dabrafenib and Trametinib** alternate BRAF inhibitors may be considered for patient intolerance or preference (encorafenib and binimetinib or vemurafenib and cobimetinib)

[d] **Nivolumab and Relatlimab** although this combination has been approved in the first line setting, it is reasonable to use in the appropriate relapsed setting, published data support activity in the second-line

Malignant Melanoma – Metastatic Second Line Progression After Dabrafenib and Trametinib



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Progression** time, rate, and site of progression should be considered when deciding on change in systemic treatment or locoregional treatment

[b] **Candidate for Dual Agent Immunotherapy** patients with ECOG performance status 0-1, lack of active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation or solid organ transplant

[c] **Extensive Disease Burden** presence of brain metastases or clinically symptomatic sites of disease

[d] **Nivolumab and Relatlimab** although this combination has been approved in the first line setting, it is reasonable to use in the appropriate relapsed setting

Malignant Melanoma – Metastatic Second Line Progression After PD-1 Alone



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Progression** time, rate, and site of progression should be considered when deciding on change in systemic treatment or locoregional treatment

[b] **BRAF Status** decision between second line targeted therapy and escalation to dual agent immunotherapy (nivolumab and relatlimab or ipilimumab and nivolumab) should take into account disease burden, rate of progression, and tolerance of prior lines of therapy

[c] **Dabrafenib and Trametinib** alternate BRAF inhibitors may be considered for patient intolerance or preference (encorafenib and binimetinib or emurafenib and cobimetinib)

[d] **Candidate for Dual Agent Immunotherapy** patients with ECOG performance status 0-1, lack of active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation or solid organ transplant

[e] **Extensive Disease Burden** presence of brain metastases or clinically symptomatic sites of disease

[f] **Nivolumab and Relatlimab** although this combination has been approved in the first line setting, it is reasonable to use in the appropriate relapsed setting

Malignant Melanoma – Metastatic Second Line Progression After Nivolumab and Relatimab



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Progression** time, rate, and site of progression should be considered when deciding on change in systemic treatment or locoregional treatment

[b] **BRAF Status** decision between second line targeted therapy or immunotherapy (ipilimumab and nivolumab) should take into account disease burden, rate of progression, and tolerance of prior lines of therapy

[c] **Dabrafenib and Trametinib** alternate BRAF inhibitors may be considered for patient intolerance or preference (encorafenib and binimetinib or vemurafenib and cobimetinib)

[d] **Candidate for Dual Agent Immunotherapy** patients with ECOG performance status 0-1, lack of active autoimmune disease, primary immune deficiency, concurrent immunosuppression (including prednisone equivalent >10mg/day) or prior allogeneic hematopoietic stem cell transplantation or solid organ transplant

Malignant Melanoma – Intracranial



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Multidisciplinary Discussion** to include Medical Oncology, Radiation Oncology, Palliative Care, and Neurosurgery

[b] **Asymptomatic Intracranial Metastases** < 3 cm in size can prompt consideration of upfront systemic therapy with monitoring by Neurosurgery and Radiation Oncology for potential of local therapy

[c] **Presence of Brain Metastases** should prompt strong consideration of ipilimumab and nivolumab as treatment option

[d] **Whole Brain Radiation Therapy** for low performance status patients (ECOG ≥3), consider whole brain radiation in consultation with Medical Oncology, Radiation Oncology, and Neurosurgery

Malignant Melanoma – Mucosal



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Systemic Imaging** to include whole body PET/CT, or CT imaging and brain MRI

[b] **Mucosal Melanoma Adjuvant Therapy** mucosal melanomas are not well represented on any large trials associated with FDA approvals; the decision to treat in an adjuvant manner off of a clinical trial should be considered carefully in depth with the patient

[c] **Assessment for KIT Mutations** complete assessment for KIT mutations and consider potential KIT targeting therapy for mucosal melanomas

[d] **Treatment of Metastatic Mucosal Melanoma** has limited clinical evidence but use of cutaneous melanoma pathways is appropriate; evidence suggest ipilimumab and nivolumab may have improved activity in mucosal melanomas

Malignant Melanoma – Ocular



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Radiation** if patient undergoes plaque brachytherapy, obtain CT of orbit with contrast prior to therapy

[b] **Risk Assessment** includes **Low Risk**: class IA, disomy 3, gain of chromosome 6p, EIF1AX mutation, T1 (AJCC); **Medium Risk**: Class IB, SF33B1 mutation, T2 and T3 (AJCC); **High Risk**: class II, monosomy 3, gain of chromosome 8q, BAP1 mutation, T4 (AJCC)

Malignant Melanoma – Uveal Metastatic or Recurrent



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Disease Limited to Liver** in select situations, hepatic resection can be considered

[b] **Metastatic Uveal Melanoma** limited data suggest ipilimumab and nivolumab have improved activity in uveal melanoma

Malignant Melanoma – Molecular Testing



Clinical trial(s) always considered on pathway. For assistance in finding a clinical trial, email CancerClinicalTrialsNavigation@va.gov.

[a] **Risk Stratification** may be obtained through either gene expression profiling analysis, chromosomal microarray, or CGP

[b] **BRAF Immunohistochemistry** for BRAF V600E may be obtained faster if clinically necessary

CGP Comprehensive Genetic Profiling

Malignant Melanoma – Molecular Testing Table

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Cutaneous Melanoma	Molecular Testing	BRAF V600E/K PCR	Local VA or locally contracted vendor	No	Tumor Tissue, Blood
	IHC	BRAF V600E mutation	Local VA or locally contracted vendor	No	Tumor Tissue
Mucosal Melanoma	Molecular Testing	BRAF V600E/K PCR KIT PCR	Local VA or locally contracted vendor	No	Tumor Tissue, Blood
	IHC	BRAF V600E mutation	Local VA or locally contracted vendor	No	Tumor Tissue
Ocular (Uveal) Melanoma	Gene Expression Profiling*	Gene expression profiling for risk stratification	Local VA or locally contracted vendor	No	Blood
	Chromosomal Micro Array*	Chromosomal micro array for risk stratification	Local VA or locally contracted vendor	No	Blood, Saliva
	Somatic NGS*	CGP using both DNA and RNA based methodology for risk stratification including GNAQ, GNA11, BAP1, PLCB4, CYSLTR2, SF3B1, EIF1AX	Tempus Foundation Medicine	Yes Yes	Tumor Tissue, Blood
	Genotyping	High resolution testing for HLA-A*02:01 for recurrent metastatic uveal melanoma only	Local VA or locally contracted vendor	No	Blood, Saliva
Acral/Lentiginous Melanoma	Molecular Testing	BRAF V600E/K PCR KIT PCR	Local VA or locally contracted vendor	No	Tumor Tissue, Blood
	IHC	BRAF V600E mutation	Local VA or locally contracted vendor	No	Tumor Tissue
* Risk stratification for Ocular melanoma could be done either by gene expression profiling, chromosomal micro array or CGP					